

Oncology Today with Dr Neil Love: Current and Future Management of Hodgkin Lymphoma

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- In the Phase III ECHELON-1 trial, brentuximab vedotin with doxorubicin/vinblastine/dacarbazine (A + AVD) significantly improved overall survival in comparison to doxorubicin/bleomycin/vinblastine/dacarbazine (ABVD) with which approximate reduction in risk of death?

 - 5%
 - 10%
 - 20%
 - 40%
- A Phase III study evaluating pembrolizumab versus brentuximab vedotin (BV) for relapsed/refractory (R/R) classic Hodgkin lymphoma (HL) demonstrated which of the following progression-free survival (PFS) outcomes?

 - PFS was significantly better with pembrolizumab
 - PFS was significantly better with BV
 - PFS was similar with both agents
- Which of the following rates best describes the overall response with the CD25-targeted antibody camidanlumab tesirine for patients with R/R HL in early-phase clinical investigation?

 - Less than 10%
 - 25%
 - 50%
 - Higher than 70%
- Which of the following statements best describes the relative incidence of second cancer with A + AVD versus ABVD in the Phase III ECHELON-1 trial for patients with Stage III or IV classical HL?

 - Incidence was lower in the A + AVD study arm
 - Incidence was lower in the ABVD arm
 - No difference in the incidence of second cancer was reported between the arms
- Which approximate overall response rate was reported with brentuximab vedotin and nivolumab as first-line therapy for older patients with HL?

 - 20%
 - 40%
 - 60%
 - 80%